Logo

American Heart Association

  18
  0


Final ID: MP578

Artificial Intelligence to Extract Structured Details from Unstructured Medical Records in a Global Heart Failure Trial

Abstract Body (Do not enter title and authors here): Background: Global clinical trials collect extensive unstructured medical records that richly describe participants’ clinical presentation, but their narrative format precludes quantitative analysis. Converting these records into structured data could reveal new insights into events like heart failure hospitalization (HFH) but is prohibitively labor intensive. Varied documentation styles, translated text, and scanned or handwritten documents challenge data extraction in clinical trials.
Research Question: Can a carefully prompted large language model (LLM) accurately extract structured data on the clinical presentation of HFHs from unstructured adjudication dossiers in a global trial?
Methods: We extracted structured data for 51 variables—symptoms, signs, laboratory values, imaging findings, and treatments—from unstructured medical record dossiers in the DELIVER trial utilizing a prompting workflow for the OpenAI o1-mini LLM. We validated LLM-extracted data with physician chart review in a random sample of 125 dossiers and calculated the accuracy, positive predictive value (PPV), and negative predictive value (NPV). A second physician reviewed 25 dossiers to assess inter-reviewer reproducibility. The validated model was applied to extract presenting features in all 1,111 HFHs in the trial.
Results: LLM-extracted data achieved high overall accuracy of 0.96 (95% CI: 0.96–0.97), PPV of 0.94 (95% CI: 0.93–0.95), and NPV of 0.97 (95% CI: 0.97–0.98) on physician validation. Accuracy exceeded 0.90 for all variables except numeric BNP and Troponin I, where errors mainly reflected confusion between biomarker subtypes (BNP vs NT-proBNP or troponin I vs T). The reproducibility of human review was 98%. In the full trial, dyspnea (92%), peripheral edema (68%), pulmonary crackles (51%), congestion on chest imaging (59%) and natriuretic peptide elevation (65%) were reported frequently. Mean peri-admission ejection fraction was 46% ± 12% (n=481 with available data), vs a baseline mean of 53% ± 9%. Intravenous diuretics were used in 85% of hospitalizations, and oral diuretic doses were increased in 45%.
Conclusion: A prompt-engineered LLM accurately extracted structured data, including signs and symptoms, laboratory and imaging data from adjudication dossiers at scale in a global clinical trial to generate a structured useable database. LLM-based data extraction could be extended to unlock quantitative insights from a wide range of narrative trial records.
  • Badrouchi, Samarra  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Mcgrath, Martina  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Mc Causland, Finnian  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Mcmurray, John  ( BHF CARDIOVASCULAR RESEARCH CENTRE , Glasgow , United Kingdom )
  • Solomon, Scott  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Cunningham, Jonathan  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Marti Castellote, Pablo-miki  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Foa', Alberto  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Claggett, Brian  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Xu, Dongchu  ( Harvard Medical School , Cambridge , Massachusetts , United States )
  • Desai, Akshay  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Ho, Jennifer  ( Harvard Medical School , Newton , Massachusetts , United States )
  • Ellinor, Patrick  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Jhund, Pardeep  ( UNIVERSITY OF GLASGOW , Glasgow , United Kingdom )
  • Author Disclosures:
    Samarra Badrouchi: DO NOT have relevant financial relationships | Martina McGrath: DO have relevant financial relationships ; Consultant:Vera Therapeutics:Active (exists now) ; Research Funding (PI or named investigator):Lexicon:Past (completed) ; Other (please indicate in the box next to the company name):Astra Zeneca, DSMB member:Active (exists now) ; Other (please indicate in the box next to the company name):Alexion, Steering Committee member:Active (exists now) | Finnian Mc Causland: DO have relevant financial relationships ; Research Funding (PI or named investigator):Novartis:Active (exists now) ; Other (please indicate in the box next to the company name):Expert Witness Rubin Anders Scientific:Active (exists now) ; Speaker:Global Learning Collaborative:Active (exists now) ; Speaker:Bayer:Active (exists now) ; Consultant:Zydus:Past (completed) ; Consultant:GSK:Active (exists now) ; Consultant:Aquapass:Active (exists now) ; Research Funding (PI or named investigator):NIH:Active (exists now) ; Research Funding (PI or named investigator):AstraZeneca:Active (exists now) ; Research Funding (PI or named investigator):Lexicon:Active (exists now) | John McMurray: DO NOT have relevant financial relationships | Scott Solomon: DO have relevant financial relationships ; Research Funding (PI or named investigator):Alexion, Alnylam, Applied Therapeutics, AstraZeneca, Bellerophon, Bayer, BMS, Boston Scientific, Cytokinetics, Edgewise, Eidos/BridgeBio, Gossamer, GSK, Ionis, Lilly,NIH/NHLBI, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Tenaya, Theracos, US2.AI:Active (exists now) ; Consultant:Abbott, Action, Akros, Alexion, Alnylam, Amgen, Arena, Askbio, AstraZeneca, Bayer, BMS, Cardior, Cardurion, Corvia, Cytokinetics, GSK, Intellia, Lilly, Novartis, Roche, Theracos, Quantum Genomics, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, Valo, Synhale, Recordati:Active (exists now) | Jonathan Cunningham: DO have relevant financial relationships ; Consultant:us2.ai:Active (exists now) ; Consultant:Occlutech:Active (exists now) ; Consultant:Edgewise Therapeuticcs:Past (completed) | Pablo-Miki Marti Castellote: DO NOT have relevant financial relationships | Alberto Foa': DO NOT have relevant financial relationships | Brian Claggett: No Answer | Dongchu Xu: DO NOT have relevant financial relationships | Akshay Desai: DO have relevant financial relationships ; Research Funding (PI or named investigator):Abbott:Past (completed) ; Consultant:River2Renal:Active (exists now) ; Consultant:Roche:Active (exists now) ; Consultant:Regeneron:Active (exists now) ; Consultant:New Amsterdam:Active (exists now) ; Consultant:Novartis:Past (completed) ; Consultant:Merck:Past (completed) ; Consultant:Medtronic:Past (completed) ; Consultant:Medpace:Active (exists now) ; Consultant:GlaxoSmithKline:Past (completed) ; Consultant:Endotronix:Active (exists now) ; Consultant:CVS:Active (exists now) ; Consultant:Boston Scientific:Active (exists now) ; Researcher:Biofourmis:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:Axon Therapies:Past (completed) ; Consultant:Avidity Biopharma:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:Alnylam:Active (exists now) ; Consultant:Abbott:Active (exists now) ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Research Funding (PI or named investigator):Novartis:Past (completed) ; Research Funding (PI or named investigator):Bayer:Active (exists now) ; Research Funding (PI or named investigator):AstraZeneca:Active (exists now) ; Research Funding (PI or named investigator):Alnylam:Active (exists now) | Jennifer Ho: DO have relevant financial relationships ; Individual Stocks/Stock Options:Pfizer:Active (exists now) ; Consultant:Lilly:Active (exists now) | Patrick Ellinor: DO have relevant financial relationships ; Research Funding (PI or named investigator):Bayer AG:Active (exists now) ; Consultant:Bayer AG:Past (completed) ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Research Funding (PI or named investigator):BMS:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Active (exists now) | Pardeep Jhund: DO have relevant financial relationships ; Consultant:AstraZeneca:Active (exists now) ; Other (please indicate in the box next to the company name):Director GCTP :Active (exists now) ; Researcher:Analog Devices :Active (exists now) ; Researcher:Roche Diagnostics:Active (exists now) ; Researcher:AstraZeneca:Past (completed) ; Researcher:Boheringer Ingelheim:Past (completed) ; Consultant:Bayer:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Emerging Applications of AI and Digital Biomarkers in Cardiovascular and Population Health

Saturday, 11/08/2025 , 12:15PM - 01:20PM

Moderated Digital Poster Session

More abstracts on this topic:
A Phase 2 Study Evaluating the Effects of Mivelsiran, an Investigational RNA Interference Therapeutic, on Hemorrhagic and Nonhemorrhagic Manifestations of Cerebral Amyloid Angiopathy

Greenberg Steven, Parikh Neal, Lee Jin-moo, Van Etten Ellis, Van Osch Matthias, Klijn Catharina, Sostelly Alexandre, Goteti Sasikiran, Sepehrband Farshid, Avbersek Andreja, Deering Robert

A ChatGLM-based stroke diagnosis and prediction tool

Song Xiaowei, Wang Jiayi, Ma Weizhi, Wu Jian, Wang Yueming, Gao Ceshu, Wei Chenming, Pi Jingtao

More abstracts from these authors:
Mode of Death in Heart Failure with Preserved Ejection across the Kidney Function Spectrum: Pooled Individual-Patient Level Analysis of 5 Trials

Bart Nicole, Pfeffer Marc, Pitt Bertram, Zannad Faiez, Zile Michael, Mcmurray John, Solomon Scott, Cunningham Jonathan, Ariss Robert, Claggett Brian, Vaduganathan Muthiah, Neuen Brendon, Beldhuis Iris, Desai Akshay, Jhund Pardeep, Mc Causland Finnian

Artificial Intelligence to Adjudicate Major Adverse Cardiovascular Events in Clinical Trials

Marti Castellote Pablo-miki, Desai Akshay, Ellinor Patrick, Ho Jennifer, Mcmurray John, Pfeffer Marc, Solomon Scott, Cunningham Jonathan, Badrouchi Samarra, Claggett Brian, Xu Dongchu, Maddah Mahnaz, Khurshid Shaan, Vardeny Orly, Lewis Eldrin, Jhund Pardeep

You have to be authorized to contact abstract author. Please, Login
Not Available